Calidi Biotherapeutics, Inc. Net Income Loss

Quick Answer

Calidi Biotherapeutics, Inc. reported Net Income Loss of -$19.91 million for the year ending 2025.

  • Calidi Biotherapeutics, Inc. showed an increase of +10.1% in Net Income Loss from 2024 to 2025.
  • This data is from Calidi Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Calidi Biotherapeutics, Inc.'s Net Income Loss has grown by 21.7%.
  • Historical annual values: Fiscal year 2025: -$19.91 million | Fiscal year 2024: -$22.14 million | Fiscal year 2023: -$29.22 million | Fiscal year 2022: -$25.43 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: